<DOC>
	<DOC>NCT01008059</DOC>
	<brief_summary>To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.</brief_summary>
	<brief_title>Alfentanil: Simultaneous Testing Pilot</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Alfentanil</mesh_term>
	<criteria>Male or nonpregnant female, 1840 yr. old Good general health with no remarkable medical conditions such as liver, kidney, heart, or lung failure BMI between 2033 Provide informed consent Known history of liver or kidney disease Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affect CYP3A (including oral birth control medications) Females who are pregnant or nursing Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction) Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential). History of bradycardia Respiratory rate &lt;10 History of significant pulmonary disease History of preexisting medical condition predisposing to respiratory depression Systolic blood pressure &lt;100 mgHg and diastolic blood pressure &lt;70mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>